Vfend® (voriconazole) – Expanded indication
January 29, 2019 - The FDA approved Pfizer’s Vfend (voriconazole), for use in pediatric and adult patients (2 years of age and older) for the treatment of invasive aspergillosis, candidemia, esophageal candidiasis, and other serious fungal infections.
Download PDF
